Skip to search formSkip to main contentSkip to account menu

PF 00299804

Known as: PF-299804, EGFR Inhibitor PF-00299804, PF-00299804-03 
A highly selective, small-molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Quinazolinones
dacomitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
The Allelic Context of the C 797 S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity toSubsequent Treatment Strategies
Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have… 
2014
2014
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent…
TPS2110 Background: Recurrent GBM has a very poor prognosis and there is an unmet need for new treatment options. EGFR is an… 
2014
2014
Abstract CT208: Absolute bioavailability of dacomitinib (PF-00299804): Comparison of oral and intravenous administration in healthy volunteers
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: Dacomitinib (D) is a highly selective… 
2012
2012
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines
SummaryBiliary tract cancer (BTC) is associated with poor survival and unresponsiveness to chemotherapy. Targeted therapies for… 
2012
2012
Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers
2012
2012
Preclinical Development Evaluation of the Antitumor Effects and Mechanisms of PF 00299804 , a Pan-HER Inhibitor , Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
Recently, HER2-directed treatment, such as trastuzumab, has shown clinical benefit in HER2-amplified gastric cancer. On the basis… 
2011
2011
Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and…
5561 Background: PF is a potent, irreversible small molecule pan-HER tyrosine kinase inhibitor (TKI) with pre-clinical antitumor… 
2010
2010
Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected…
7537 Background: Efficacy of gefitinib as first-line tx of adv NSCLC with epidermal growth factor receptor (EGFR) mutation (mu… 
2010
2010
Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs).
3026 Background: Cross-talk between human epidermal growth factor receptor (HER) and insulin-like growth factor type I receptor… 
2010
2010
American Society of Clinical Oncology--46th annual meeting.
The 46th Annual Meeting of the American Society of Clinical Oncology, held in Chicago, included topics covering new therapeutic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)